This cross-sectional study evaluated the prevalence of GLP-1 receptor agonist use and misuse among people with eating disorders in the US.
Cross-sectional design limits causal inference; abstract provides no specific prevalence figures or sample details.
Clinicians prescribing GLP-1 receptor agonists should screen for eating disorders, given emerging concerns about potential misuse in this population.
Explore related topics
